Previous 10 | Next 10 |
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi ® has experienced 8 Consecutive Quarters of Double-Digit Prescription Growth Acquisition Adds Another...
2023-12-29 10:00:03 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Healthcare and utilities could perform better in 2024 - analyst Arcus, Bristol-Myers, ...
2023-12-20 08:29:09 ET More on Palatin Tech Palatin Tech Q1 2024 Earnings Preview Palatin falls on common stock and warrants offering Seeking Alpha’s Quant Rating on Palatin Tech For further details see: Palatin rises as it completes sale of Vylees...
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million PR Newswire Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline ...
2023-12-18 16:19:23 ET More on Palatin Tech Palatin falls on common stock and warrants offering Seeking Alpha’s Quant Rating on Palatin Tech For further details see: Palatin receives notice of acceptance of listing standards compliance plan from NYSE American
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American PR Newswire CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class med...
2023-12-04 17:10:25 ET More on Palatin Tech Seeking Alpha’s Quant Rating on Palatin Tech For further details see: Palatin Technologies files to sell 2.48M shares of common stock for holders
2023-11-14 17:00:06 ET Palatin Technologies, Inc. (PTN) Q1 2024 Earnings Conference Call November 14, 2023 11:00 AM ET Company Participants Carl Spana – President and Chief Executive Officer Steve Wills – Executive Vice President, Chief Financial Office...
2023-11-14 07:35:41 ET More on Palatin Tech Palatin Technologies, Inc. (PTN) Q4 2023 Earnings Call Transcript Palatin Tech Q1 2024 Earnings Preview Palatin falls on common stock and warrants offering Seeking Alpha’s Quant Rating on Palatin Tech ...
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Cale...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Sympt...
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 PR Newswire CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 20...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...